Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Breast Cancer, Lung cancer, Pancreatic caner(cytotoxic chemotheraphy) More
Novel small molecule inhibitors of c-Met signaling; these small molecules selectively bind to c-Met and have an IC50 in the micromolar range. More
These cell lines (based on the widely used B16 murine melanoma cell line) were transduced with retroviral vectors encoding cDNA for either CXCR4 or CCR10 under control of a TET-dependent promoter. More
These hybrid antibody molecules can be engineered with a variety of small synthetic molecules, and the combination of immunogenic properties results in compounds with powerful target destruction or imaging capabilities. More
The technology describes the humanization of a murine anti-carcinoma antibody CC49 which has been shown to react with Tumor Associated Glycoprotein 72 (TAG-72), an antigen which is expressed on human breast, ovarian, colorectal, and other carcinomas. More
The present invention describes cytotoxic compounds with an intracellular target that can selectively enter tumor cells through specific receptors on the cell surface. More
Screening tool for the detection of breast and other cancers More
A vector to be used for transfection and purification of human soluble FcRn receptor More
This technology describes several antibodies, both polyclonal and monoclonal, to the prolactin receptor. More
Identification and characterization of three (3) novel fully human monoclonal antibodies, which may be used to prevent binding of IGF-I to its concomitant receptor IGFIR, consequently, modulating diseases such as cancer. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Jan 2011 - 4 pages - $500
Mar 2011 - 5 pages - $500
Feb 2008 - $2,500
Dec 2008 - 200 pages - $1,390
Dec 2010 - 34 pages - $5,700
Nov 2010 - 40 pages - $500
Jul 2011 - 36 pages - $3,800
May 2011 - 7 pages - $500
Jul 2011 - 940 pages - $500
Jul 2011 - 271 pages - $500
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Adenocarcinoma
- Breast cancer, other
- Ductal carcinoma in situ
- Invasive ductal breast cancer
- Invasive lobular breast cancer
- Lobular carcinoma in situ
- Paget's Disease
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us